Because it can be combinatorially phosphorylated on six hydroxyl groups, the cyclic poly-alcohol d-myoinositol is an ideal cellular information carrier. Its many derivatives form an 'inositol code' , the most prominent members of which are soluble inositol phosphates (InsPs) and their membrane-bound lipid counterparts, the phosphoinositides 1,2 (BOX 1; FIG. 1). In 1983, the identification of inositol-1,4,5-trisphosphate (Ins(1,4,5)P 3 ; hereafter referred to as InsP 3 for simplicity) as a second messenger that mediates receptor-induced Ca 2+ mobilization in most mammalian cells first showed that soluble InsPs have physiological roles 3 . More recently, intriguing functions for several higher-order InsPs have been identified (BOX 1). Moreover, the phosphoinositide lipids phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) and PtdIns(3,4,5)P 3 (hereafter referred to as PtdInsP 3 ) regulate signalling by many receptors in many cell types [4] [5] [6] [7] [8] [9] . PtdInsP 3 is generated by phosphoinositide 3-kinases (PI3Ks) and metabolized by lipid phosphatases, including phosphatase and tensin homologue (PTEN), SH2-domain-containing inositol-5-phosphatase 1 (SHIP1) and SHIP2 (ReF. 10). The key to phosphoinositide function is the phosphorylation status of their cytoplasm-exposed InsP headgroups. These bind to specific domains in signalling or cytoskeletal proteins to control their membrane recruitment. Defects in phosphoinositide metabolism or function contribute to many diseases, including cancer, leukaemias, immunodeficiencies and autoimmune, neurodegenerative, allergic and inflammatory disorders 4-9 .
Because it can be combinatorially phosphorylated on six hydroxyl groups, the cyclic poly-alcohol d-myoinositol is an ideal cellular information carrier. Its many derivatives form an 'inositol code' , the most prominent members of which are soluble inositol phosphates (InsPs) and their membrane-bound lipid counterparts, the phosphoinositides 1,2 In 1983, the identification of inositol-1,4,5-trisphosphate (Ins(1,4,5)P 3 ; hereafter referred to as InsP 3 for simplicity) as a second messenger that mediates receptor-induced Ca 2+ mobilization in most mammalian cells first showed that soluble InsPs have physiological roles 3 . More recently, intriguing functions for several higher-order InsPs have been identified
. Moreover, the phosphoinositide lipids phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) and PtdIns(3,4,5)P 3 (hereafter referred to as PtdInsP 3 ) regulate signalling by many receptors in many cell types [4] [5] [6] [7] [8] [9] . PtdInsP 3 is generated by phosphoinositide 3-kinases (PI3Ks) and metabolized by lipid phosphatases, including phosphatase and tensin homologue (PTEN), SH2-domain-containing inositol-5-phosphatase 1 (SHIP1) and SHIP2 (ReF. 10) . The key to phosphoinositide function is the phosphorylation status of their cytoplasm-exposed InsP headgroups. These bind to specific domains in signalling or cytoskeletal proteins to control their membrane recruitment. Defects in phosphoinositide metabolism or function contribute to many diseases, including cancer, leukaemias, immunodeficiencies and autoimmune, neurodegenerative, allergic and inflammatory disorders [4] [5] [6] [7] [8] [9] .
Here, we review recent findings that have identified important roles for soluble inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P 4 ; hereafter referred to as InsP 4 ) in the immune system. Decreased InsP 4 production in leukocytes causes immunodeficiency in mice and might contribute to inflammatory vasculitis in Kawasaki disease. We first briefly introduce InsP 4 and the kinases that produce it (reviewed further in . Next, we review recently discovered roles for InsP 4 in controlling T cell, B cell and neutrophil development and function [16] [17] [18] [19] [20] [21] [22] [23] [24] . We propose a model in which InsP 4 , at least in part, regulates leukocyte development by controlling the functions of PI3Ks, PTEN, SHIP1 and SHIP2 as a soluble PtdInsP 3 analogue, and by limiting store-operated Ca 2+ entry (SOCE) in B cells and neutrophils. We then discuss how the seemingly opposite functions of InsP 4 in thymocytes and developing B cells establish appropriate selection 'windows' that are crucial for the generation of competent, self-tolerant T and B cell repertoires. Finally, we review the therapeutic opportunities of targeting InsP 4 and summarize important open questions regarding this intriguing soluble messenger molecule.
InsPs in immunoreceptor signalling
The cellular concentrations of multiple InsPs are altered after immunoreceptor stimulation
. For example, T cell receptor (TCR) or B cell receptor (BCR) stimulation activates phospholipase Cγ1 (PLCγ1) and, in B cells, PLCγ2, which then hydrolyse membrane PtdIns(4,5)P 2 into two second messenger molecules: the membrane lipid diacylglycerol (DAG) and soluble InsP 3 
Phosphoinositides
A family of phosphorylated derivatives of the membrane lipid phosphatidylinositol that contain a hydrophobic diacylglycerol backbone esterified to a polar inositol headgroup.
Second messenger
A signalling molecule such as InsP 3 or DAG that is produced by a primary effector, usually an enzyme, that is in turn activated by a signal transducer downstream of a transmembrane receptor after its engagement by a first messenger ligand (for example, peptide-MHC complexes in the case of the T cell receptor). The second messenger can then activate one or more secondary effectors that further transmit signals into the cell.
Kawasaki disease
(Also known as mucocutaneous lymph node syndrome). An acute, self-limited vasculitis of infants and the leading cause of acquired heart disease among children in developed countries.
Box 1 | Higher-order inositol phosphate metabolism and functions
The figure summarizes important aspects of the metabolism of higher-order inositol phosphates (InsPs), with known enzymes, in mammals (for additional details, see ReFS 44, 74, 76, 114) . Red boxes denote enzymes with genetically documented functions in immunocytes; pale and dark yellow boxes denote InsPs found in immunocytes; dark yellow boxes denote antigen receptor-modulated InsPs 17, 18, 23, 25, 45, [58] [59] [60] [61] [62] [63] [64] [65] [66] 115 .
Higher-order InsPs have recently been implicated in regulating important cellular processes in eukaryotes:
• Protein membrane recruitment (by InsP 4 , reviewed here)
• Apoptosis (by inositol-pyrophosphates (PP-InsPs)) 116, 117 • Cytoskeletal and vesicle dynamics, exocytosis, endocytosis and cytokinesis (by InsP 4 and InsP 6 and by PP-InsPs in Schizosaccharomyces pombe) 44, [117] [118] [119] • Cyclin-cyclin-dependent kinase inhibition in the Saccharomyces cerevisiae phosphate-starvation response (by InsP 7 ) 120 • Protein-protein interactions (by InsP 4 ) 121 • Ca 2+ mobilization (by InsP 3 and InsP 4 , reviewed here, and by InsP 6 ) 122, 123 • ClC-3 chloride channels (by Ins(3,4,5,6)P 4 ) 124 .
• O 2 -haemoglobin binding in nucleated erythrocytes (by Ins(1,3,4,5,6)P 5 ) 44 • Antioxidant function 34 • mRNA export from the nucleus (by InsP 6 in yeast) 114, 125, 126 • Translation termination (by InsP 6 in yeast) 127 • Gene transcription (by InsP 7 in yeast) 128 • mRNA editing (by InsP 6 )
129
• Chromatin remodelling (by InsP 4 , InsP 5 and InsP 6 in yeast) 130, 131 • DNA repair (by InsP 6 in non-homologous end joining and by PP-InsPs in yeast hyper-recombination) 132, 133 • Telomere length (by PP-InsPs in yeast) 134, 135 InsPs may modulate protein function by acting as:
• Essential structural co-factors
• Triggers for induced fit or allosteric structural changes
• Direct antagonistic competitors for phosphoinositide ligands
• Non-enzymatic protein phosphorylating agents (PP-InsPs) 136 Most of these findings were obtained in yeast or non-leukocyte cell types (reviewed in ReFS 1, 14, 33, [44] [45] [46] [47] 74, 76, 117, 137) .
InsP pyrophosphorylation further expands the inositol code and enables pyrophosphate transfer onto protein substrates. It will be interesting to determine whether InsP 3 3-kinase (ITPK) deficiency affects specific higher-order InsP levels in leukocytes, and to analyse whether higher-order InsPs mediate aspects of InsP 4 function. In one study, concanavalin A-stimulated Itpkb -/-thymocytes showed altered InsP 4 , Ins(1,3,4)P 3 and InsP 2 levels. InsP 3 and bulk InsP 5 levels seemed to be unaffected 23 . DAG, diacylglycerol; IPK1, inositol-1,3,4,5,6-pentakisphosphate 2-kinase; IPMK, InsP multikinase; ITPK1, inositol-1,3,4-trisphosphate 5/6 kinase; PI3K, phosphoinositide 3-kinase; PLCγ, phospholipase Cγ; PtdIns, phosphatidylinositol; PTEN, phosphatase and tensin homologue; R, fatty-acid side chain; SHIP, SH2-domain-containing inositol-5-phosphatase. 
IL-2-inducible T cell kinase
(ITK). A T cell and NK cell expressed Tec family non-receptor protein tyrosine kinase that is involved in T cell receptor signalling.
Long-term potentiation
A long-lasting enhancement of synaptic transmission between two neurons thought to underlie learning and memory. (FIG. 1) . DAG recruits and activates key signalling mediators such as the RAS-activator RAS guanyl nucleotidereleasing protein 1 (RASGRP1) and members of the protein kinase C (PKC) family . Binding of InsP 3 to  InsP 3 receptors mobilizes Ca   2+ . PLCγ, RASGRP1, PKCs and Ca 2+ mobilization are all important for lymphocyte development and function 29, 30 . TCR and BCR engagement also trigger membrane recruitment and activation of PI3Ks, which phosphorylate PtdIns(4,5)P 2 at position 3 of its inositol ring to form PtdInsP 3 . PtdInsP 3 then recruits several important signalling proteins to cellular membranes by binding to their pleckstrin-homology (PH) domains or other domains 31 . Among these, the Tec family protein tyrosine kinases IL-2-inducible T cell kinase (ITK), tyrosine kinase expressed in hepatocellular carcinoma (TEC) and Bruton's tyrosine kinase (BTK) are essential for antigen receptor signalling. In particular, Tec family protein tyrosine kinases phosphorylate and activate PLCγ1 and PLCγ2 (ReFS 27, 28) . Furthermore, binding of PtdInsP 3 to the PH domain of AKT controls membrane recruitment and activation of this key regulator of lymphocyte survival, proliferation, differentiation and activation 5, 6, 32 .
The crucial roles of PI3Ks, PTEN, SHIP1 and SHIP2 in leukocyte development, survival, proliferation and function, as well as in leukaemia, indicate the importance of carefully controlling PtdInsP 3 turnover in leukocytes 5, 6, 32 
Itpkc
-/-thymocytes have unaltered InsP 3 3-kinase activity 23 . In humans, however, genetic data may indicate an intriguing role for ITPKC in inhibiting peripheral T cell function 42 . No roles for IPMK in the immune system have been reported (TABLe 1) , although IPMK might regulate Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling in flies 43 . Biochemical studies and genetic studies in yeast suggest many potential molecular functions for InsP 4 (reviewed in ReFS 1, [11] [12] [13] [14] [33] [34] [35] [44] [45] [46] [47] 2) . Interestingly, InsP 4 alone could not induce SOCE in these cells 51 . Conversely, InsP 4 directly activated Ca 2+ channels in endothelial and neuronal cells [54] [55] [56] [57] . So, InsP 3 3-kinases . Ca 2+ binds calmodulin (CaM), which binds to and activates InsP 3 3-kinases (ITPKs) and calcineurin (CaN) 139 . CaN dephosphorylates and activates the transcription factor nuclear factor of activated T cells (NFAT) 29 . ITPKs phosphorylate InsP 3 to form Ins(1,3,4,5)P 4 (InsP 4 ), which may have several functions (based on data from Itpkb -/-mouse thymocytes 17, 18, 23 , ITPKC-mutant human T cells 42 and biochemical studies [11] [12] [13] 25, 51, 83, 85 ). Binding of InsP 4 to one subunit of an ITK oligomer allosterically increases the PH domain affinity of all ITK subunits for PtdInsP 3 . This promotes ITK membrane recruitment, causing full PLCγ1 activation and sufficient DAG production to activate the RAS-extracellular signal-regulated kinase (ERK) pathway and trigger thymocyte positive selection. ITPKB deficiency perturbs this feedback activation through decreased InsP 4 production and decreased ITK recruitment to the membrane. ITPKC deficiency might cause peripheral T cell hyperactivity, possibly through increased NFAT signalling. The cause could be altered InsP 3 turnover by ITPKC or InsP 4 -inhibited 5-phosphatases or other perturbed functions of InsP 4 or its derivatives 45, 51 
APC, antigen-presenting cell; GADS, GRB2-related adaptor protein; IL-2, interleukin-2; RASGRP1, RAS guanyl nucleotide-releasing protein 1; SLP76, SH2-domain-containing leukocyte protein of 76 kDa.
Feedback loop
A cause and effect circuit in which several processes occur in sequence and in which the output of a downstream process promotes or inhibits an upstream process, forming a circular signalling loop. Inhibitory loops (negative feedback) can increase the stability and accuracy of a signalling system by correcting unwanted changes. Activation loops (positive feedback) can amplify a signal by increasing the gain of the signal-transducing machinery. [68] [69] [70] [71] (FIG. 1) . However, the PTEN and SHIP deficiency of Jurkat T cells 72 , which contain an InsP 4 -inhibitable 5-phosphatase 51 , indicates that other enzymes are also important.
Neonatal thymic organ culture (NTOC)
In addition to functioning as an InsP 3 3-kinase, or a non-conventional PI3K of uncertain physiological relevance 73 , IPMK can also phosphorylate InsP 3 , InsP 4 , Ins(1,4,5,6)P 4 and Ins(1,3,4,6)P 4 at positions 3, 5 or 6 to generate Ins(1,3,4,5,6)P 5 (ReFS 11 -14,25,33-36,39,74) . This is probably the main eukaryotic pathway for producing higher-order InsPs 14, [75] [76] [77] 
. Because of the position of InsP 4 early in this pathway, some of its functions might actually be mediated by other higher-order InsPs, a possibility that warrants further investigation.
As we discuss here, studies of Itpkb -/-mice have recently identified important in vivo functions of ITPKB and InsP 4 (or possibly its derivatives) and have provided new insight into how InsP 4 functions molecularly.
InsP 4 controls T cell development

Itpkb
-/-mice, independently generated by two groups, have severe peripheral T cell lymphopenia and immunodeficiency. The cause is a profound block of T cell development at the CD4 + CD8 + double-positive (DP) thymocyte stage owing to impaired positive selection 17, 18, 23 . Retrovirally expressed 17 wild-type but not catalytically impaired ITPKB restored the development of Itpkb -/-thymocytes. Hence, the catalytic activity of ITPKB is required in thymocytes. During positive selection, low-avidity or -affinity TCR engagement induces DP thymocyte maturation. High-avidity or -affinity TCR stimulation induces apoptosis during negative selection. This prevents the maturation of detrimental self-reactive T cells. Most TCR signalling mediators are involved in both processes. One study reported defective negative selection in Itpkb -/-mice expressing the transgenic HY TCR 23 . However, the higher level of thymocyte deletion seen in the control mice than in Itpkb -/-mice probably reflects the presence of mature thymocytes in the control but not Itpkb -/-sample, and not increased negative selection, because mature T cells can induce DP thymocyte death through a cytokine storm 30 . Moreover, the HY TCR system might have limited physiological relevance: because expression of this transgenic, mature TCR starts before the DP stage, it alters the phenotype of DP thymocyte precursors and causes deletion of DP thymocytes 78 . By contrast, endogenous mature TCRs are expressed mainly by DP thymocytes and at later stages of development, and substantial negative selection occurs after the DP stage. Therefore, detailed studies in more appropriate models are required to conclusively determine whether ITPKB has a role in negative selection. An essential role for ITPKB in positive but not negative selection would be intriguing. Of all the TCR signalling mediators studied so far, only RASGRP1, calcineurin B, extracellular signal-regulated kinase 1 (ERK1) and ERK2 (collectively referred to as ERK in this Review) are exclusively required for positive but not negative selection 30, 79, 80 . A recent study found an intriguing association of a human ITPKC allele that decreases ITPKC mRNA splicing efficiency and abundance with susceptibility to Kawasaki disease , the leading cause of childhood-acquired heart disease in developed countries 42 . 
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Other InsPs
Acute-phase patients have T cell infiltration into the coronary artery wall and increased interleukin-2 (IL-2) production, which indicates that T cell hyperactivation could contribute to the disease. ITPKC mRNA levels increased after PMA and ionomycin stimulation 33, 42 . Indicative of a potential function for ITPKC in limiting peripheral T cell activation that could be perturbed in patients with Kawasaki disease, ITPKC overexpression decreased, and ITPKC knockdown increased, phytohaemagglutinin-induced and PMA-induced nuclear factor of activated T cells (NFAT) activation and IL2 mRNA expression in Jurkat T cells 42 . The mechanism is unknown but could involve some of the aforementioned controversial roles of InsP 3 3-kinases or InsP 4 in Ca 2+ mobilization; it could also involve other functions of ITPKC, InsP 4 or its derivatives 14, 44, 45 41, 90, 91 . Testing all of these possibilities will require simultaneous ITPK inhibition through small molecules or their conditional co-disruption.
InsP 4 controls B cell development B cell development in the bone marrow of chemically induced Itpkb
-/-mice is unchanged. However, the numbers of all splenic B cell subsets are markedly decreased, including transitional B cells undergoing selection, and mature follicular and marginal zone B cells. Follicular B cells in Itpkb -/-mice have downregulated IgM levels, and half of the splenic IgD + cells express the plasma cell marker CD138 (ReFS 16,19 ). These cells are at a preplasma cell checkpoint stage; a similar population is enriched in models of B cell tolerance 92 . Indeed, mature B cells from Itpkb -/-mice share many features with B cells from soluble hen egg lysozyme (sHEL)-HEL-specific immunoglobulin (IgHEL) and p-azophenylarsonate (Ars)-IgArs transgenic models of B cell anergy 93 . These include IgM downregulation, impaired BCR-driven proliferation, decreased BCR-induced upregulation of surface CD69, CD86 and MHC class II molecule expression, and decreased antibody responses to T cell-independent antigens 16, 19, 21 . These defects are specific to BCR stimulation; Itpkb -/-B cell responses to lipopolysaccharide (LPS) or CD40-specific antibodies were normal. These findings indicate that ITPKB might control B cell selection and tolerance induction.
In the sHEL-IgHEL and Ars-IgArs anergy models, constitutive self-antigen expression causes BCR desensitization, impaired BCR-mediated activation of proximal tyrosine kinases (LYN and spleen tyrosine kinase (SYK)) and of downstream effectors including PLCγ2, decreased InsP 3 production and impaired Ca 2+ influx 94, 95 . By contrast, Miller et al. 16 found that anergic B cells from Itpkb -/-mice had normal BCR-induced activation of LYN, BTK, PLCγ2, ERK1, ERK2, IκB kinase-α (IKKα) and IKKβ, with unaltered InsP 3 production but increased BCR-induced SOCE 16 (FIG. 3) . Normal Ca 2+ responses to thapsigargin, which opens SOCE channels by depleting endoplasmic reticulum Ca 2+ stores, indicated that SOCE channels were . In particular, the impaired ionomycin response found by Marechal et al. 21 but not by Miller et al. 16 indicates a more extreme phenotype, perhaps owing to the selection of aberrant B cells over time or to differences in housing, health status, genetic background or age of the mice used in both studies.
InsP 4 broadens the B cell repertoire by limiting SOCE.
Based on these data, we propose a model in which ITPKB, by production of InsP 4 , functions as a feedback inhibitor of BCR-induced SOCE (FIG. 3) . Increased SOCE in Itpkb -/-mice alters B cell selection and tolerance induction. The outcome depends on the BCR affinity for self antigens. ITPKB deficiency enhances Ca 2+ signalling and promotes positive selection for low-affinity selfspecific BCRs, such as IgHEL; it induces anergy of B cells expressing weakly to moderately self-reactive BCRs in non-transgenic mice or IgHEL mice; and it induces deletion of normally anergic B cells with more strongly self-reactive BCRs, as seen in the sHEL-IgHEL system Crossing Itpkb -/-mice with appropriate autoimmuneprone strains or BCR-transgenic mice will address conclusively whether ITPKB deficiency promotes or prevents autoimmune disease.
Roles of ITPkB in the innate immune system
Recent studies have shown important functions of ITPKB in the innate immune system. Contrasting with its roles in promoting lymphocyte development, ITPKB may limit myelopoiesis; moreover, it controls neutrophil function.
ITPKB limits myelopoiesis.
Itpkb mRNA is expressed by all mouse haematopoietic stem and progenitor cell populations 20 (FIG. 4) . Itpkc mRNA is expressed by all myeloid lineages and minimally by haemato poietic stem cells and common lymphoid progenitors. Common myeloid progenitors and megakaryocyte-erythrocyte progenitors express low levels of Itpka mRNA. Itpkb -/-mice have increased proliferation of granulocytemonocyte progenitors, increased neutro phil production and increased peripheral blood neutrophil numbers 20 (FIG. 4) . Thus, ITPKB limits myeloid differentiation in vivo. The precise mechanism is unclear but might 42 . In Itpkb -/-mice, perturbed splenic B cell development yields decreased numbers of B cells and increased anergy 16, 19, 21 . Conversely, Itpkb deficiency causes GMP accumulation, the generation of hyperactive neutrophilic granulocytes with decreased viability and slightly decreased erythrocyte numbers 20, 22, 47 . Mast cells express ITPKB and produce InsP 4 after stimulation 115 ; small molecule ITPK inhibition might increase their activation 24, 109 , but the target selectivity of the low-affinity ITPK inhibitors used is unknown and genetic studies in mast cells are required.
involve inhibition of the PI3K target AKT, the PH domain of which can bind PtdInsP 3 , PtdIns(3,4)P 2 20 despite the fact that PI3K-AKT signalling (which is increased in Itpkb -/-bone marrow-derived neutrophils) inhibits neutrophil spontaneous death 47 . Interestingly, ITPKB deficiency promoted neutrophil recruitment into the inflamed peritoneal cavity in an acute peritonitis model. However, clearance of the injected bacteria was not markedly improved 22 . Subsequent studies showed slightly decreased bacterial clearance in vivo, but increased killing of serumopsonized bacteria in vitro, by Itpkb -/-neutrophils. Serum from Itpkb -/-mice, which contains less opsonizing IgG than wild-type serum owing to the aforementioned B cell defects, facilitated killing of bacteria less efficiently than did wild-type serum 47 . This indicates that ITPKB limits neutrophil recruitment and in vitro function. However, in vivo, ITPKB probably functions in several different cell types to control peritonitis responses. Although not investigated in detail, the 
Some InsP 4 functions could thus be mediated by InsP 4 -derived InsPs rather than by InsP 4 itself. Based on the recently identified, intriguing functions of higherorder InsPs in non-lymphoid cells
, studies of higher-order InsPs in leukocytes should be exciting.
Quantitative kinetic analyses of InsP 4 , PtdInsP 3 and higher-order InsP levels in Itpkb -/-leukocytes, the identification of all relevant InsP targets through bioinformatics or affinity chromatography, ITPKB structure and function analyses and conditional ITPK co-disruption in relevant cell types are required to fully understand how ITPKs control leukocyte development and function, and to identify all underlying molecular mechanisms.
Although ITPKB is required for the efficient selection of both T and B cells, its role in promoting thymocyte positive selection strikingly contrasts with its inhibitory role in BCR signalling in B cell selection 17, 18, 23 . In T cells, ITPKB probably extends the repertoire by amplifying weak TCR signals that would otherwise fail to elicit positive selection. In B cells, ITPKB expands the repertoire by inhibiting BCR signalling and preventing the deletion of B cells that would otherwise fail to develop. That a single gene achieves repertoire extension in opposite manners in T and B cells is fascinating. It probably reflects important differences in the rate-limiting steps for selection of T cells (positive selection) versus B cells (negative selection). Interestingly, these differences mirror the differential effects of ITPKB on SOCE in both cell types. Feedback inhibition of SOCE by InsP 4 does not control thymocyte positive selection but is crucial for extending the B cell repertoire. Determining whether this difference results from differences in InsP 4 [101] [102] [103] or by PH domainindependent BTK activation in B cells 5 . Moreover, the possibility that sorted splenic B cell subpopulations from Itpkb -/-mice might have stronger differences in BTK and PLCγ phosphorylation than the subtle effects found in total splenic B cells 16 remains to be investigated. T cells, B cells and neutrophils are key mediators of inflammatory diseases, including rheumatoid arthritis, diabetes and asthma. Defects in their development or function can cause immunodeficiencies, such as AIDS or X-linked agammaglobulinaemia, or promote cancer. T cells, moreover, cause organ-transplant rejection. All three cell types require ITPKB for their development or function. We therefore next discuss the therapeutic opportunities and liabilities of targeting ITPKs pharmacologically.
Therapeutic relevance
Because of their key roles in leukocyte development and function, cancer cell survival, proliferation and migration and other pathological processes such as obesity, PI3Ks are popular therapeutic targets. The first PI3K inhibitors recently entered clinical trials for the treatment of inflammatory diseases and cancer. However, the ubiquitous functions of PI3Ks mean there is significant potential for toxicity, which might limit therapeutic applications 5, 7, 8, 104 . Autoimmune phenotypes in mice with altered PI3K function raise additional concerns for long-term therapies 5 . Moreover, the ability of IPMK to function as a wortmannin-insensitive PI3K 73 (ReFS 23,75 ). This suggests that preservation of higher-order InsP production through the broadly expressed, structurally diverse IPMK 77 might decrease the risk of potential side effects of selective ITPK inhibition.
Their biochemical properties and available highthroughput assays make ITPKs good potential drug targets [11] [12] [13] 25, 33, 105 . Compared with protein and lipid kinases, distinct structural features of the ITPKs could allow the rational design of highly selective, ATP-or substratecompetitive or allosteric ITPK inhibitors 11, 33, 85, [106] [107] [108] . Indeed, several groups have identified small-molecule ITPK inhibitors, some of which have high selectivity for ITPKs over IPMK 33, [109] [110] [111] [112] . The strong inhibitory effects of ITPKB deficiency on thymocytes and B cells make broad immunosuppression for the treatment of transplant rejection or severe autoimmune diseases the most likely use for ITPKB inhibitors. A true evaluation of their therapeutic potential awaits validation with human cells. ITPKB is highly expressed by human peripheral T cells 33 , and the recent implication of genetic ITPKC polymorphisms in Kawasaki disease 42 indicates the pathophysiological importance of ITPKs in humans. Although the precise roles of ITPKs in disease aetiology are not known, a negative role for ITPKC in human T cell activation 42 could pose a potential liability for broad ITPK inhibitors. Alternatively, this negative function of ITPKC might allow the development of ITPKC inhibitors as adjuvants to promote T cell function in immunodeficiencies and infectious diseases.
Neutrophils have important roles in infections, allergies, inflammatory diseases and autoimmunity 113 . Hence, the pathophysiological relevance of the increased neutrophil chemotaxis and superoxide production but decreased neutrophil viability in Itpkb -/-mice 22 requires exploration. Increased neutrophil recruitment in peritonitis models in Itpkb -/-mice 22 could possibly indicate opportunities for ITPKB inhibition for antiinfective therapies but might pose liabilites for immunosuppression. The feasibility of neutrophil modulation depends on the involvement of T and B cells in the targeted diseases as, despite the increased neutrophil number, clearance of intraperitoneal-injected bacteria was unaltered or even decreased in Itpkb -/-mice, possibly as a result of decreased serum IgG titres 22, 47 . Altogether, the validation of ITPKB as a therapeutic target will require more detailed analyses of its role in innate immune cells and in peripheral T cells, analyses of Itpkb -/-mice in relevant disease models and proof-ofconcept studies with potent and selective small-molecule ITPKB inhibitors.
Two decades after its discovery, Itpkb -/-mice have shown important in vivo signalling functions for InsP 4 and identified the first physiological InsP 4 effectors 84 .
Like many other important discoveries, these findings pose more questions than they answer
. In non-immune cells and yeast, higher-order InsPs have recently been implicated in several important cellular processes 1, 25, 74, 84 
. Thus, the prospect of investigating the functions of the higher-order InsPs in leukocytes (BOX 1) and their potential contributions to InsP 4 signalling is particularly exciting 25 . Without any doubt, deciphering the lymphocyte 'inositol code' remains a rich area of research. • Tec family protein tyrosine kinases have key roles in peripheral T cell differentiation and function 27, 28 . Are PtdInsP 3 -binding Tec family kinases in peripheral T cells controlled by InsP 4 ?
• InsP 4 can act as a precursor for many other InsPs (see also BOX 1 
